Report: Current Stock Reports

Obtaining the status of Associate Partner within IPCEI Med4Cure
May 29, 2024

Conclusion of funding agreement with the National Centre for Research and Development
May 28, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
May 23, 2024

Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress
May 14, 2024

Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting
April 10, 2024

Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis
March 29, 2024

Ryvu project recommended for funding by the Polish Agency for Enterprise Development
March 27, 2024

Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error
March 8, 2024

Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank
March 6, 2024

Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting
March 6, 2024

Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS
February 14, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
February 9, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
February 7, 2024

Achievement of the second milestone under license agreement with Exelixis Inc.
February 5, 2024

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 5, 2024

Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax
January 31, 2024

Registration of series K subscription warrants of the Company with the National Depository for Securities
January 31, 2024

Publication dates for periodic reports in 2024
January 18, 2024

Take-up of series K subscription warrants by the European Investment Bank
January 18, 2024

Resignation of a member of the Company’s Supervisory Board from his position
January 3, 2024